TG Therapeutics announced the completion of its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under this program, the company repurchased approximately 3.5 million shares of its common stock.
The average price paid for these repurchased shares was $28.55 per share. This action demonstrates the company's commitment to returning value to shareholders and reflects management's belief in the intrinsic value of the stock.
Furthermore, the company's Board of Directors authorized a new share repurchase program, allowing for the acquisition of up to an additional $100 million of TG Therapeutics' common stock. This new program underscores continued confidence in the multibillion-dollar potential of BRIUMVI and the company's long-term growth prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.